Paeds Vivas · paediatric-dermatology
Impetigo and bacterial skin infection — branching viva
Branching structured-oral viva on impetigo and bacterial skin infection: the non-bullous and bullous forms, the exfoliative-toxin and desmoglein-1 pathophysiology, clinical diagnosis, stepwise topical and oral treatment matched to extent and region, drainage-first abscess management, community-acquired MRSA, decolonisation, and the post-streptococcal glomerulonephritis complication with the skin-strep-versus-throat-strep distinction.
On this page & tools
Target exams
Opening question
Examiner: Take me through this child. What is the diagnosis, and what is your frame for managing it? [1]
Candidate: The most likely diagnosis is non-bullous impetigo — the honey-coloured, weeping crust spreading from the nose across the cheek and onto the sibling, in an otherwise well, afebrile child, is the classic presentation of the commonest bacterial skin infection of childhood. My frame is three-layered: treat the individual lesion with the least antibiotic that will work, control the household and school spread, and watch for the post-streptococcal complications. Because the child is well with localised lesions, this is a community-managed case with a short topical course and clear advice on exclusion and hygiene. [1] [2]
Examiner: How do you classify impetigo, and which form is dangerous? [1]
Candidate: Two forms. Non-bullous impetigo is about seventy percent — the honey-coloured crust, caused by Staphylococcus aureus or group A streptococcus. Bullous impetigo is about thirty percent — flaccid bullae caused exclusively by exfoliative-toxin-producing S. aureus. The dangerous end of the same spectrum is staphylococcal scalded skin syndrome, where the toxin circulates systemically in a neonate or young infant and causes widespread tender erythema and sheet-like desquamation. This child has the benign form; I would still examine for any sign of deeper extension or toxin-mediated appearance. [1] [8]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References7Show ledgerHide ledger
- [1]Koning S; van der Sande R; Verhagen AP; van Suijlekom-Smit LW; et al Interventions for impetigo. Cochrane Database Syst Rev, 2012.PMID 22258953
- [2]Bowen AC; Mahe A; Hay RJ; Andrews RM; et al The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma. PLoS One, 2015.PMID 26317533
- [3]Bowen AC; Tong SY; Andrews RM; O'Meara IM; et al Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region. Lancet, 2014.PMID 25172376
- [5]Miller LG; Daum RS; Creech CB; Young D; et al Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med, 2015.PMID 25785967
- [6]Talan DA; Mower WR; Krishnadasan A; Abrahamian FM; et al Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess. N Engl J Med, 2016.PMID 26962903
- [7]Kaplan SL; Forbes A; Hammerman WA; Lamberth L; et al Randomized trial of bleach baths plus routine hygienic measures vs. routine hygienic measures alone for prevention of recurrent infections. Clin Infect Dis, 2014.PMID 24265356
- [8]Gray L; Hansen AM; Cipriano SD Pediatric Staphylococcal Scalded Skin Syndrome: A Systematic Review of the Literature to Inform Work-Up and Management. Pediatr Dermatol, 2025.PMID 40650480